Valneva (NASDAQ:VALN) Sees Strong Trading Volume

Shares of Valneva SE (NASDAQ:VALN) saw unusually-high trading volume on Tuesday . Approximately 9,549 shares were traded during mid-day trading, a decline of 3% from the previous session’s volume of 9,804 shares.The stock last traded at $8.34 and had previously closed at $8.56.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Valneva in a research note on Wednesday, August 14th.

Valneva Trading Down 6.0 %

The company has a quick ratio of 2.15, a current ratio of 2.63 and a debt-to-equity ratio of 0.97. The company has a market cap of $551.24 million, a P/E ratio of -19.31 and a beta of 2.20. The firm’s 50 day moving average is $7.33 and its two-hundred day moving average is $7.70.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC raised its position in shares of Valneva SE (NASDAQ:VALN) by 42.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,252 shares of the company’s stock after acquiring an additional 26,248 shares during the quarter. AlphaCentric Advisors LLC owned about 0.13% of Valneva worth $649,000 as of its most recent SEC filing. 11.39% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.